Bill Haney adds another $133M to Skyhawk's coffers, as the RNA startup guns for the clinic
A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Haney is reeling in another $133 million for Skyhawk Therapeutics. And it sounds like he’s got the S-1 papers in his back pocket.
Skyhawk unveiled the latest round led by Fidelity Management and Research on Tuesday morning, which Haney says is likely the company’s last venture round before going public. Other big name investors like GreatPoint Ventures and Rock Springs Capital also chipped in.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.